AMFI Registered MFD · ARN-130934 · Mutual fund investments are subject to market risks. CA Amit Kumar Jain · +91 93522 44475 Poornima Jain · +91 92525 44475 support@plenitude.co.in हिंदी

Sigachi Industries Limited share price

Sigachi Industries Limited manufactures and sells microcrystalline cellulose and cellulose powder in India. The company provides cellulose-based products under the HiCel, AceCel, CoatCel, GloCel, and BARETab brand names to pharmaceutical, nutraceutical, cosmetic, and chemical industries. It also provides croscarmellose sodium, pharmaceutical coatings, nutritional premix and food solutions, and allied trade business, as well as operations and maintenance services. In addition, the company exports its products. Sigachi Industries Limited was incorporated in 1989 and is headquartered in Hyderabad, India.Read more
HealthcareDrug Manufacturers - Specialty & GenericNSE: SIGACHIISIN INE0D0K01022
16 Oct 2026, 3:29 PM IST₹27.52▼ 0.17 (0.61%)
  • Market Cap₹ 1,053 Cr.
  • Current Price₹ 27.52
  • High / Low₹ 41 / 17
  • Stock P/E41.1
  • Book Value₹ 14
  • Dividend Yield0.00 %
  • ROCE-13.1 %
  • ROE-14.60 %
  • Face Value₹ 1.0
More figures (10)
  • EPS (TTM)₹ 0.67
  • Price / Book2.03
  • OPM7.6 %
  • Debt / Equity0.31
  • Sales growth (3Y)16.5 %
  • Profit growth (3Y)—
  • Promoter holding41.9 %
  • EV / EBITDA24.5
  • Beta0.46
  • All-time high₹ 96

Price chart

Returns1M3M6MYTD1Y3Y CAGR5Y CAGR
SIGACHI-11.68%+12.19%+17.96%-11.57%-28.09%-10.81%—
Nifty 50-0.31%-3.85%-4.34%-11.42%-9.53%+5.46%+4.76%

Price returns only (dividends not included). Prices from NSE via Yahoo Finance; may be delayed.

Quick take

  • Sigachi Industries Limited is in the Drug Manufacturers - Specialty & Generic industry (Healthcare), with a market value of ₹1,053 crore.
  • It trades at 41.1 times its last 12 months' earnings and 2.0 times book value.
  • Revenue grew 16.5% a year over the last 3 years.
  • Return on equity was -14.6% and return on capital employed -13.1% in the latest year.
  • Debt was 0.31 times shareholders' equity.
  • The share price is 32.6% below its 52-week high and down 28.1% over one year.
  • Promoters and insiders hold about 41.9%; institutions about 0.0%.

Pros

  • Sales have grown 16.5% a year over the last 3 years.
  • Borrowings are moderate at 0.31 times shareholders' equity.

Cons

  • Return on equity has been low: 5.1% on average over the last 3 years.
  • Promoter holding has fallen by 11.80 points over 3 years, to 36.69%.
  • Trades at 41.1 times earnings, above its 3-year median of 9.1.
  • The company has not paid a dividend recently.

Pros and cons are generated automatically from the reported figures. They are observations, not a recommendation to buy or sell.

AI analysis

Plenitude AI reads the figures on this page and explains them in plain language. It does not say whether to buy or sell.

About Sigachi Industries Limited

Sigachi Industries Limited manufactures and sells microcrystalline cellulose and cellulose powder in India. The company provides cellulose-based products under the HiCel, AceCel, CoatCel, GloCel, and BARETab brand names to pharmaceutical, nutraceutical, cosmetic, and chemical industries. It also provides croscarmellose sodium, pharmaceutical coatings, nutritional premix and food solutions, and allied trade business, as well as operations and maintenance services. In addition, the company exports its products. Sigachi Industries Limited was incorporated in 1989 and is headquartered in Hyderabad, India.

Employees
1,400
Head office
Hyderabad

Peer comparison

HealthcareDrug Manufacturers - Specialty & Generic

S.No.CompanyCMP ₹P/EMar Cap ₹ CrDiv Yld %NP Qtr ₹ CrQtr Profit Var %Sales Qtr ₹ CrQtr Sales Var %ROCE %
1.Sigachi Industries27.5241.11,0530.008—121-5.44-13.1
2.Sun Pharmaceutical Industries1,758.8034.94,21,9950.912,89534.6515,18418.4817.9
3.Divi's Laboratories9,144.5083.02,42,7580.3390236.253,08019.1519.0
4.Torrent Pharmaceuticals4,558.9072.81,73,4060.835663.284,92154.859.1
5.Zydus Lifesciences1,123.0025.01,12,0200.09940-19.747,80224.0319.0
6.Laurus Labs2,060.10101.81,11,3100.12362123.942,02629.1019.5
7.Cipla1,325.1031.81,07,0510.98786-39.187,1192.3314.9
8.Dr. Reddy's Laboratories1,233.0031.01,02,7070.66444-68.728,071-5.5614.2
9.Aurobindo Pharma1,666.9026.095,9100.001,03314.299,1068.6513.5
10.Mankind Pharma2,275.5046.093,9880.0057429.124,03112.8913.7
Median: 62 Co.1,712.8534.19,9150.1668014.296,02015.6814.6

Companies in the same industry; the median covers every company in it that we hold figures for. Tap a heading to sort. Sorting and comparing are ways to explore data, not recommendations.

Quarterly Results

Consolidated figures in ₹ crore /

₹ CrJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
859911110496125139128128110117122121
6878888875108106100104103111105105
Operating Profit162123162117332924861617
OPM %19%22%20%16%22%14%24%22%19%7%5%13%14%
21272152242011
Interest1223324333343
Depreciation2333335554454
Profit before tax1518201716272723-1017-2810
26%17%18%12%22%21%23%29%-42%1%19%
1115161513212116-10111-088
EPS in Rs3.544.930.510.480.400.660.650.36-2.630.280.010.200.18
Raw filing

Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Latest quarter on the right.

Profit & Loss

Consolidated figures in ₹ crore /

₹ CrMar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
250302399488478471
197243322388424425
Operating Profit5359771005446
OPM %21%19%19%20%11%10%
37122185
Interest148121414
Depreciation3711161817
Profit before tax52547092-8823
22%20%18%24%-12%
40445770-8326
EPS in Rs15.4414.161.812.06-2.140.67
Dividend Payout %7%5%5%

Compounded Sales Growth

3 Years:
17%
TTM:
-10%

Stock Price CAGR

3 Years:
-11%
1 Year:
-28%

Return on Equity

4 Years:
8%
Last Year:
-15%

Financial years ending March; TTM = the last four quarters. Source: the company's results filed with NSE, as reported. Tap a row marked + for its breakdown. Dividend payout = dividends paid in the year ÷ net profit.

Balance Sheet

Consolidated figures in ₹ crore, as at 31 March

₹ CrMar 2023Mar 2024Mar 2025Mar 2026
Equity Capital31333838
Reserves238397563484
68151142162
37113103157
Total Liabilities374694846841
173305363345
CWIP511064876
149284435420
Total Assets374694846841

Source: Yahoo Finance (compiled from the annual reports). Tap a row marked + for its breakdown.

Cash Flows

Consolidated figures in ₹ crore, financial years ending March

₹ CrMar 2023Mar 2024Mar 2025Mar 2026
291327-43
-92-161-93-5
26172812
Net Cash Flow-372415-46
Free Cash Flow-72-72-16-88

Free cash flow = cash from operations − capital expenditure. Source: Yahoo Finance.

Ratios

RatioMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROE—16.2%16.4%13.5%-14.6%
ROCE—19.2%14.8%15.6%-13.1%
Operating margin—17.4%17.8%20.1%7.6%
Net margin—14.4%14.3%14.2%-17.1%
Debt / equity—0.260.350.240.31
Current ratio—2.381.672.131.44
Debtor days—97137137171
Inventory days—104115143100
Days payable—47785480
Cash conversion cycle—154174226191
Working capital days—12411515691

Computed from the reported statements: ROE on average equity; ROCE = EBIT / (total assets − current liabilities). Debtor days = receivables ÷ sales × 365; inventory and payable days use cost of goods sold; cash conversion cycle = debtor + inventory − payable days; working capital days = (current assets − current liabilities) ÷ sales × 365.

Shareholding Pattern

Numbers in percentages · as filed with NSE each quarter

  • Promoters 36.69%
  • FIIs 1.25%
  • Public 62.05%
%Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters48.49%48.49%45.43%45.43%44.71%44.71%44.14%44.14%40.48%39.70%36.69%36.69%
0.95%0.22%2.06%1.56%1.58%0.16%0.08%2.89%3.10%3.33%1.30%1.25%
50.56%51.29%52.51%53.01%53.71%55.12%55.78%52.97%56.41%56.97%62.01%62.05%
No. of Shareholders79,86297,0311,37,5061,37,1921,52,0451,56,3971,60,5571,51,2022,05,2621,94,7771,94,5591,88,986

Source: shareholding patterns filed by the company with NSE. Public = non-institutional holders. Tap a row marked + for its breakdown.

Documents

Announcements

All announcements on NSE →

Concalls & investor meets

Filings made by the company with NSE; documents open on NSE's website.

Key dates

Ex-dividend date
16 Sep 2025
Latest quarter
30 Jun 2026
Financial year end
31 Mar 2026

Trade with our broking desk

Open a trading & demat account through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539; NSE AP0153037862, BSE AP01095201177059). Execution and service only: no tips or research.

Latest news

From the company (NSE)

Headlines from news publishers (via Google News) and the filings of the company with NSE; they open on the source website. Headlines with price targets or buy/sell calls are left out. News is for information only and is not a recommendation.

Questions about Sigachi Industries Limited

What is the share price of Sigachi Industries Limited today?
Sigachi Industries Limited (SIGACHI) last traded at ₹27.52 on NSE (16 Oct 2026, 3:29 PM IST). Prices may be delayed.
What is the market cap of Sigachi Industries Limited?
About ₹1,053 crore at the latest price.
What is the P/E ratio of Sigachi Industries Limited?
About 41.1 times its earnings over the last 12 months.
Is Sigachi Industries Limited a good investment?
We do not give views on individual shares. Whether any share suits you depends on your goals, time horizon and risk appetite; for long-term goals, a diversified mutual fund is often a simpler way to own shares. Investments in securities markets are subject to market risks.
How can I buy Sigachi Industries Limited shares?
You need a trading and demat account with a SEBI-registered stock broker. We can help you open one through Parshvanath Investments, an Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539). We provide execution and account service only, not tips or research.
Important. Prices from NSE via Yahoo Finance. Quarterly and annual results, shareholding and documents are taken from the filings the company made with NSE; balance sheet, cash flow and valuation figures are compiled by Yahoo Finance; ratios are computed by us from them. Figures may be delayed or revised. This page is for information only: it is not research, a recommendation or an offer to buy or sell any security. Investments in securities markets are subject to market risks; read all related documents carefully before investing. Plenitude Connect Private Limited is an AMFI-registered Mutual Fund Distributor (ARN-130934); share broking is offered through Parshvanath Investments, Authorised Person of Master Capital Services Ltd (SEBI Reg. INZ000210539).
Talk to us

Have a question about this topic?

Tell us a little about your situation and an expert will call you back, usually within 2 hours on business days.

Experts are available Mon–Sat, 10 AM – 7 PM

Book your free wealth consultation

  • 100% free
  • No obligation
  • Reply within 2 hours
+91
Join 2,000+ investors who plan with Plenitude
Your details are private and never shared.
WhatsApp Book free call